The Xiphophorus-derived antibody, XMEL, shows sensitivity and specificity for human cutaneous melanoma but is not a prognostic marker

Journal of Cutaneous Pathology

Volumn 24, Issue 10, 1997, Pages 620-627

  Vielkind, J R ^a,b   Huhn, K ^a   Tron, V A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMB 45; PROTEIN TYROSINE KINASE; RECEPTOR PROTEIN;

ARTICLE; DIAGNOSTIC ACCURACY; FISH; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MELANOMA; PROGNOSIS; PROSTATE ADENOCARCINOMA; SARCOMA; SKIN CARCINOGENESIS;

EID: 0030697829     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1997.tb01093.x     Document Type: Article

References (37)

1. Rigel DS, Kopf AW, Friedman RJ. The rate of malignant melanoma in the United States: are we making an impact? J Am Acad Dermatol 1987: 17: 1050.
2. Koh HK. Cutaneous melanoma. N Engl J Med 1991: 325: 171.
3. Clark WH, Jr, Elder DE, Guerry D, Epstein MN, Green MH, van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Human Pathol 1984: 15: 1147.
4. Fountain JW, Bale SJ, Housman DE, Dracopoli NC. Genetics of melanoma. Cancer Surv 1990: 9: 645.
5. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-22. Science 1992: 258: 1148.
6. Fountain JW, Karayiorgou M, Ernstoff M, et al. Homozygous deletions within human chromosome hand 9p21 in melanoma. Proc Natl Acad Sci USA 1992: 88: 10557.
7. Healy E, Rehman I, Angus B, Rees JL. Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes, Chromosomes Cancer 1995: 12: 152.
8. Herbst RA, Weiss J, Ehnis A, Cavenee WK, Arden KC. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res 1994: 54: 3111.
9. Isshiki K, Elder DE, Guerry D, Linnenback AJ. Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer 1993: 8: 178.
10. Thompson FH, Emerson J, Olson S, et al. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 1995: 83: 93.
11. Balaban G, Herlyn M, Guerry D, et al. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet 1984: 11: 429.
12. Cowan JM, Halaban R, Franke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 1988: 80: 1159.
13. Nancarrovv DJ, Mann GJ, Holland EA, et al. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 1993: 53: 936.
14. Goldstein AM. Dracopoli NC, Ho EC, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p and evidence for genetic heterogeneity. Am J Hum Genet 1993: 52: 537.
15. Hussussian CJ, Streuwing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994: 8: 15.
16. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994: 264: 436.
17. Kamb A, Shatttuck-Eidens D, Eeles R, et al. Analysis of the p16 (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994: 8: 22.
18. Gruis NA, van der Velden PA, Sandkuiji LA, et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995: 10: 351.
19. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletions at p16/CDKN2 in primary human tumours. Nat Genet 1995: 11: 210.
20. Reed JA, Loganzo F, Jr, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995: 55: 2713.
21. Grand CG, Gordon M, Cameron G. Neoplasm studies. VII. Cell types in tissue culture of fish melanocytic tumors compared with mammalian melanomas. Cancer Res 1941: 1: 660.
22. Grand CG, Cameron G. Tissue culture studies of pigmented melanomas: fish, mouse, and human. In: The Biology of Melanomas. (Spec Publ). NY Acad Sci 1948: 4: 171.
23. Wittbrodt J, Adam D, Malitschek B, et al. Novel puative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus. Nature 1989: 341: 415.
24. Woolcock BW, Schmidt BM, Kallman KD, Vielkind JR. Differences in transcription and promoters of XMRK-1 and XMRK-2 genes suggest a role for XMRK-2 in pigment pattern development in the platyfish Xiphophorus maculatus. Cell Growth Differ 1994: 5: 575.
25. Vielkind U. Genetic control of cell differentiation in platyfish-swordtail melanomas. J Exp Zool 1976: 196: 197.
26. Vielkind JR, Kallman KD, Morizot DC. Genetics of melanomas in Xiphophorus fishes. J Aquatic Animal Health 1989: 1: 68.
27. Vielkind JR. Progression from pigment cell patterns to melanomas in platyfish-swordtail hybrids - multiple genetic changes and a theme for tumorigenesis. In: Milo GE, Casto BC, Shuler CF, eds. Tranformation of Human Epithelial Cells: Molecular and Oncogenetic Mechanisms. Boca Raton, Florida: CRC Press, 1992: 285.
28. Nairn RS, Kazianis S, McEntire BB, Della Coletta L, Walter RB, Morizot DC. A CDKN2-like polymorphism in Xiphophorus LG V is associated with UV-B-induced melanoma formation in platyfish-swordtail hybrids. Proc Natl Acad Sci USA 1996: 93: 13042.
29. Vielkind JR, Tron VA, Schmidt BM, et al. A putative marker for human melanoma - A monoclonal antibody derived from the melanoma gene of the Xiphophorus melanoma model. Am J Pathol 1993: 143: 656.
30. Tron VA, Crawford R, Vielkind JR. The melanoma specific XMEL antigen is expressed in dysplastic naevi. Melanoma Res 1997: 7: 1.
31. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986: 123: 195.
32. Breslow A. Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Sur 1970: 172: 902.
33. Ruiter DJ, Broecker EB. Immunohistochemistry in the evaluation of melanocytic tumours. Semin Diagn Pathol 1993: 10: 76.
34. de Witt PE, Morette S, Koenders PG, et al. Increasing epidermal growth factor receptor expression in human melanoctyic tumor progression. J Invest Dermatol 1992: 99: 168.
35. Natali PG, Nicotra MR, Di Renzo MF, et al. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 1993: 68: 746.
36. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992: 52: 197.
37. Gutman M, Singh RK, Radinsky R, Bar-Eli M. Intertumoral heterogeneity of receptor-kinase expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res 1994: 14: 1759.